Ketamine One Announces Lifting of Management Cease Trade Order
KetamineOne Capital Limited (KONEF), based in Vancouver, has had its management cease trade order lifted by the British Columbia Securities Commission, effective immediately. This follows the company's filing of audited annual financial statements for the fiscal year ending July 31, 2021, on December 13, 2021. KetamineOne aims to become a leader in mental health treatments across North America by consolidating medical clinics. Their subsidiary, KGK Science Inc., focuses on clinical research in pharmaceuticals and psychedelic medicine.
- Management cease trade order lifted, allowing for operational transparency.
- Filing of audited annual financial statements for FY ending July 31, 2021, indicating compliance with regulatory requirements.
- Strategic focus on consolidating medical clinics to enhance market presence in mental health treatment.
- No significant financial metrics provided, leaving uncertainty on fiscal health.
- -
VANCOUVER, British Columbia, Dec. 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its management cease trade order granted by the British Columbia Securities Commission on November 1, 2021, was lifted effective immediately following the filing on SEDAR on December 13, 2021 of the Company's audited annual financial statements and accompanying management's discussion and analysis for the fiscal year ended July 31, 2021.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
SOURCE: KetamineOne Capital Limited
FAQ
What does the lifting of the management cease trade order mean for KONEF?
When did KetamineOne file its audited financial statements?
What is the focus of KetamineOne's business?
How does KGK Science Inc. contribute to KetamineOne's mission?
